{"entity":{"id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","aka":[],"tldr":"Low-grade serous ovarian cancer is a slow-growing, RAS-driven type of ovarian cancer that resists chemotherapy but responds to hormone blockers and MEK-pathway drugs.","summary":"About 5-10% of serous ovarian cancers; younger patients, KRAS/BRAF/NRAS mutations in ~30-50%, wild-type TP53, strong ER expression, low proliferation. Chemotherapy response rates are under 25%; endocrine therapy and MEK/RAF pathway inhibition (trametinib in GOG 281; avutometinib + defactinib, approved 2025) are the mainstays. Contrast with high-grade serous carcinoma.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Ovarian_cancer","links":[{"label":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer (Lancet 2022)","url":"https://doi.org/10.1016/S0140-6736(21)02175-9"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["kras"],"drugs":["avutometinib-defactinib","letrozole"],"companies":[],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Cancer biology"},"route":"/terms/lgsoc/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/"},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/"}],"pathway":[{"id":"invasion-ecm-degradation","kind":"pathway","name":"Invasion: proteases, adhesion & the invasive front","route":"/pathways/invasion-ecm-degradation/"},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"}],"trial":[{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/"}]}}